NCT00297921撤回1 期
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
研究概览
简要总结
Prospective, nonrandomized, noncomparative, open-label, multicenter, 2-stage clinical study designed to determine the overall response (combined complete remission, complete remission with incomplete blood count recovery, partial remission, or blast response) rate following tandutinib therapy in 2 groups of patients with newly diagnosed Acute Myelogenous Luekemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, at least 18 years of age
- •Unequivocal histologic or cytologic diagnosis of AML (based on the WorldHealth Organization [WHO] and/or FAB classifications), excluding acute promyelocytic leukemia (FAB M3).
- •AML patients with a history of antecedent MDS or MPD are eligible for treatment in this study.
- •In the opinion of the investigator is ineligible for or has declined treatment with standard induction therapy
- •ECOG performance status of equal to or less then 3
- •Ability to voluntarily provide written informed consent
- •Determination of the presence or absence of a FLT3-ITD mutation before enrollment once it is ascertained that determination of FLT3-ITD mutation status is required to avoid exceeding enrollment in either patient group
排除标准
- •Presence of an active malignancy other than AML at the time of study entry
- •Documented or suspected central nervous system leukemia involvement
- •Known gastrointestinal disease that could interfere with the absorption of oral tandutinib
- •Severe central nervous system, pulmonary, renal, or hepatic disease not related to AML
- •Myocardial infarction within 6 months of enrollment or New York Heart Association (NYHA) Class III or Class IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia or active conduction system abnormalities
- •QTc >500 milliseconds (ms)
- •Family history of or congenital QTc prolongation
- •Pretreatment laboratory test values as follows:
- •Total bilirubin >2.5 x the upper limit of normal (ULN)
- •Alanine aminotransferase (ALT) >2.5 x the ULN
- •Serum creatinine >4.0 mg/dL
- •Known or suspected infection with human immunodeficiency virus
- •Known active infection with hepatitis B or hepatitis C
- •Known or suspected primary muscular or neuromuscular disease (eg, muscular dystrophy or myasthenia gravis)
- •Receipt of prior antineoplastic therapy for leukemia, except that prior therapy with the following is allowed:
- •Leukapheresis
- •Treatment for hyperleukocytosis with hydroxyurea
- •Receipt of prior antineoplastic therapy for MDS, except that prior therapy with the following is allowed:
- •Growth factor/cytokine support
- •Lenalidomide (Revlimid™)
- •Thalidomide (Thalomid®)
- •Azacitidine (Vidaza®)
- •Decitabine (Dacogen)
- •Receipt of prior antineoplastic therapy for MPD, except that prior therapy with the following is allowed:
- •Interferon alpha
- •Anagrelide (Agrylin®)
- •Hydroxyurea
- •Antineoplastic, experimental, or radiation therapy within 3 weeks before Day 1, except that hydroxyurea for the treatment of hyperleukocytosis is permitted
- •Major surgery within 2 weeks before Day 1
- •Men or women of childbearing potential unwilling to use adequate contraception from screening to 30 days after the last dose of tandutinib
- •A woman who is pregnant or breast feeding. Confirmation that the patient is not pregnant must be established by a negative serum or urine B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during the screening period. Pregnancy testing is not required for postmenopausal or surgically sterilized women.
- •Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
研究者
相似试验
已完成
2 期
Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLCJPRN-jRCT2080224898EMD Serono Research & Development Institute, Inc.90
进行中（未招募）
2 期
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerEsophageal AdenocarcinomaEsophageal Squamous Cell CancerSiewert Type 1 GEJ CancerPancreatic CancerNCT05945823Taiho Oncology, Inc.53
进行中（未招募）
1 期
Ponatinib for Treatment of Patients with CP-CML after treatment with other TKI has failedAdult patients (age = 18) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) who have proven to be resistant or intolerant to prior first line Tyrosine Kinase Inhibitor TreatmentMedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2016-000618-30-DEGWT-TUD GmbH54
已完成
2 期
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic LeukemiaRecurrent Skin CancerSquamous Cell Carcinoma of the SkinStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaNCT00563290National Cancer Institute (NCI)7
已完成
2 期
A Phase II, two arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)locally advanced or metastic non-small cell lung carcinoma10038666lung cancerNL-OMON52430Merck3